ArticleVaccines2022
The Evolution of Medical Countermeasures for Ebola Virus Disease: Lessons Learned and Next Steps.
Article in Vaccines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06841614 (Evaluation of the Efficacy of a Post-exposure Prophylaxis), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Efficacy of a Post-exposure Prophylaxis (PEP) Strategy in Contacts at High Risk of Developing Ebola Virus Disease (EVD)
Who cites it
17 citing papers in PubMed.
- Species breadth is a preparedness metric: lessons from the 2026 Bundibugyo virus disease outbreak.Emerging microbes & infections · 2026Article
- Identification of Host Gene Transcripts by Machine Learning and Their Application to Predict Outcome in Ebola Virus Disease.The Journal of infectious diseases · 2026Article
- A small molecule inhibits Ebola virus entry through glycoprotein stabilization.Nature communications · 2026Article
- Ebola virus disease in the modern era: pathogenesis, therapeutic advances, vaccine strategies, and global health preparedness.Infection · 2026Review
- Rwanda's National Reference Laboratory Operational Capacity during the 2024 Marburg Virus Disease Outbreak Response.Tropical diseases, travel medicine and vaccines · 2026Article
- Access to licenced vaccines for high-threat infectious diseases: a scoping review and interpretive analysis of Ebola virus disease.BMC infectious diseases · 2026Article
- Long-term Sequelae in Ebola Virus Disease Survivors Receiving Anti-Ebola Virus Therapies in the Democratic Republic of the Congo: A Prospective Cohort Study.Open forum infectious diseases · 2025Article
- Sudan Virus Persistence in Immune-Privileged Organs of Nonhuman Primate Survivors.Emerging infectious diseases · 2025Article
- Evaluation of Vaccines and Therapeutics Against Ebolaviruses in the Domestic Ferret.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Beyond early warning: towards greater granularity in the use of event-based surveillance for public health emergencies.BMC public health · 2024Article
- How to prepare for the next inevitable Ebola outbreak: lessons from West Africa.Nature medicine · 2024Article
- Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches.Infectious diseases and therapy · 2024Review
- Modeling Supply and Demand Dynamics of Vaccines against Epidemic-Prone Pathogens: Case Study of Ebola Virus Disease.Vaccines · 2023Article
- Understanding knowledge, attitudes and practices on Ebola Virus Disease: a multi-site mixed methods survey on preparedness in Rwanda.BMC public health · 2023Article
- The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs.NPJ vaccines · 2023Article
- Development of a rapid image-based high-content imaging screening assay to evaluate therapeutic antibodies against the monkeypox virus.Antiviral research · 2023Article
- Ebanga™: The most recent FDA-approved drug for treating Ebola.Frontiers in pharmacology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The Ebola virus disease outbreak that occurred in Western Africa from 2013-2016, and subsequent smaller but increasingly frequent outbreaks of Ebola virus disease in recent years, spurred an unprecedented effort to develop and deploy effective vaccines, therapeutics, and diagnostics. This effort led to the U.S. regulatory approval of a diagnostic test, two vaccines, and two therapeutics for Ebola virus disease indications. Moreover, the establishment of fieldable diagnostic tests improved the speed with which patients can be diagnosed and public health resources mobilized. The United States government has played and continues to play a key role in funding and coordinating these medical countermeasure efforts. Here, we describe the coordinated U.S. government response to develop medical countermeasures for Ebola virus disease and we identify lessons learned that may improve future efforts to develop and deploy effective countermeasures against other filoviruses, such as Sudan virus and Marburg virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.